A leading biotech company sought to evaluate market receptivity for its breakthrough Phase III drug in a rare hematology disorder.
CRA approach
- Review available data to establish market landscape in the context of an expected competitor launch in expanded indication
- Develop research materials and screening criteria for execution of payer and KOL interviews
- Conduct interviews to determine value perception of drug in the new indication and understand likely pricing and market access (PMA) outcomes
- Analyze research findings to develop insights and deliver recommendations to address the strategic business questions
Client impact
- Provided global and geographic-specific assessment of the marketplace for the expansion, assessment of anticipated competitor positioning, evidence requirements, unmet needs assessment, and issues framework
- Provided consolidated insights regarding payer receptivity of the potential expanded indication, including cross-market and local perspectives
- Delivered recommendations on value perception, PMA strategy, and evidence requirements